Standout Papers

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients ... 2015 2026 2018 2022 468
  1. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial (2015)
    Craig H. Moskowitz, Auayporn Nademanee et al. The Lancet

Immediate Impact

3 from Science/Nature 73 standout
Sub-graph 1 of 22

Citing Papers

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Colorimetric sensing for translational applications: from colorants to mechanisms
2024 Standout
2 intermediate papers

Works of Andy Chi being referenced

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
2015 Standout

Author Peers

Author Last Decade Papers Cites
Andy Chi 404 371 76 168 9 563
Zhen Fan 384 336 89 135 8 570
Edward Agura 345 326 98 188 16 599
D F Moravec 463 234 45 168 7 513
Manuel F. Rosado 328 244 85 110 14 483
R Giardini 503 322 133 123 9 644
G. P. Canellos 398 257 50 145 15 603
J Pierson 513 339 140 108 13 645
I Tabah 409 372 49 81 10 506
M. Bast 547 342 65 135 10 593
Patti Cohen 385 243 40 61 10 537

All Works

Loading papers...

Rankless by CCL
2026